Regeneron acquires bankrupt 23andMe for $256M, taking over its DNA database and services while pledging to uphold privacy ...

Regeneron has been busy, with two health tech deals announced this week: One is about genetic data and one about AI. Both of ...

On May 15, 2025, a jury returned a verdict finding Amgen Inc. (“Amgen”) liable for antitrust violations and awarding Regeneron Pharmaceuticals, ...

In its announcement of the acquisition, Regeron claimed it would ensure that customers’ personal data including genetic and ...

On May 8, 2025, the Boston Bar Association hosted its annual White Collar Crime Conference, a reoccurring theme of which was ...

Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...

Regeneron Pharmaceuticals has agreed to acquire 23andMe’s consumer genetics business and assets for $256 million, following ...

The biotech company bought the genetic testing company for $256 million.

Investors burned by President Trump’s trade fight now have to contend with a spending megabill that risks swelling the ...

The bankrupt genetic-testing firm will hand over its entire data bank, including DNA samples of around 15 million people. Regeneron has said it will abide by 23andMe’s privacy policy, allowing ...

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...